{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:22:57Z","timestamp":1790446977286,"version":"4.1.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clineuro.2023.107850","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T05:19:37Z","timestamp":1687670377000},"page":"107850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs)"],"prefix":"10.1016","volume":"231","author":[{"given":"Xinyu","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin. Med (Lond. )"},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clineuro.2023.107850_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2021.118225","article-title":"An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue","volume":"238","author":"Tackley","year":"2021","journal-title":"NeuroImage"},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib6","first-page":"434","article-title":"Clinical features of diffuse leptomeningeal glioneuronal tumor with rapid blindness misdiagnosed as NMOSD and literature review, SN comprehensive","volume":"1","author":"Xiao","year":"2019","journal-title":"Clin. Med."},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/practneurol-2012-000237","article-title":"A practical guide to the treatment of neuromyelitis optica","volume":"12","author":"Palace","year":"2012","journal-title":"Pract. Neurol."},{"issue":"10","key":"10.1016\/j.clineuro.2023.107850_bib8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","article-title":"Relapsing neuromyelitis optica: long term history and clinical predictors of death","volume":"80","author":"Cabre","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.clineuro.2023.107850_bib10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"14","key":"10.1016\/j.clineuro.2023.107850_bib12","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1177\/1352458519888609","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea","volume":"26","author":"Kim","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"24","key":"10.1016\/j.clineuro.2023.107850_bib13","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.clineuro.2023.107850_bib14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","article-title":"Incidence and prevalence of NMOSD in Australia and New Zealand","volume":"88","author":"Bukhari","year":"2017","journal-title":"J. Neuol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2023.107850_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"issue":"19","key":"10.1016\/j.clineuro.2023.107850_bib16","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","article-title":"Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan","volume":"89","author":"Houzen","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/jnnp-2017-317321","article-title":"Nationwide epidemiological study of neuromyelitis optica in Japan","volume":"89","author":"Miyamoto","year":"2018","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2023.107850_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.msard.2017.10.015","article-title":"Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence","volume":"19","author":"Hor","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"17","key":"10.1016\/j.clineuro.2023.107850_bib19","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder in Korea: population based study","volume":"35","author":"Lee","year":"2020","journal-title":"jkms"},{"issue":"12","key":"10.1016\/j.clineuro.2023.107850_bib20","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1177\/1352458514521503","article-title":"Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India","volume":"20","author":"Pandit","year":"2014","journal-title":"Mult. Scler. J."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cen3.12458","article-title":"Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: A multicenter, retrospective study","volume":"9","author":"Holroyd","year":"2018","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2023.107850_bib22","doi-asserted-by":"crossref","unstructured":"W. Bukhari, E. Khalilidehkordi, D.F. Mason, M.H. Barnett, B.V. Taylor, M. Fabis-Pedrini, A.G. Kermode, S. Subramanian, P. Waters, S.A. Broadley, W. Bukhari, E. Khalilidehkordi, D.F. Mason, M.H. Barnett, B.V. Taylor, M. Fabis-Pedrini, A.G. Kermode, S. Subramanian, P. Waters, S.A. Broadley, D. Abernethy, S. Bhuta, S. Blum, M. Boggild, K. Boundy, B.J. Brew, F. Brilot, W.J. Brownlee, C.S. Bundell, H. Butzkueven, W.M. Carroll, C. Chen, L. Clarke, A. Coulthard, R.C. Dale, C. Das, K. Dear, D. Fulcher, D. Gillis, S. Hawke, R. Heard, A.P.D. Henderson, S. Heshmat, S. Hodgkinson, S. Jimenez Sanchez, T.J. Kilpatrick, J. King, C. Kneebone, A.J. Kornberg, J. Lechner-Scott, M.-W. Lin, C. Lynch, R.A.L. Macdonell, M.P. Marriott, P.A. McCombe, C. O\u2019Gorman, J.D.E. Parratt, M.P. Pender, J. Pereira, J.D. Pollard, K.M. Prain, S. Ramanathan, S.W. Reddell, C. Shaw, R.A. Silvestrini, M. Slee, J. Spies, J. Stankovich, I. Sutton, A. Vincent, S. Vucic, M. Walsh, E. Willoughby, R.C. Wong, M. Woodhall, E.M. Yiu, A. The, N.M.O.C. New Zealand, NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand, Journal of Neurology 269(2) (2022) 836\u2013845.","DOI":"10.1007\/s00415-021-10665-9"},{"issue":"14","key":"10.1016\/j.clineuro.2023.107850_bib23","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sep\u00falveda","year":"2017","journal-title":"Mult. Scler. J."},{"issue":"24","key":"10.1016\/j.clineuro.2023.107850_bib24","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib25","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007746","article-title":"Epidemiology of NMOSD in Sweden from 1987 to 2013","volume":"93","author":"Jonsson","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.clineuro.2023.107850_bib26","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00415-013-6926-y","article-title":"The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom","volume":"260","author":"Jacob","year":"2013","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-G\u00f3mez","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2023.107850_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.msard.2017.10.007","article-title":"Neuromyelitis optica spectrum disorders in Iran","volume":"18","author":"Eskandarieh","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00281-018-0723-8","article-title":"Sex differences in autoimmune disorders of the central nervous system","volume":"41","author":"Gold","year":"2019","journal-title":"Semin. Immunopathol."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.clineuro.2023.107850_bib33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/jnnp-2017-317202","article-title":"Low body mass index can be associated with the risk and poor outcomes of neuromyelitis optica with aquaporin-4 immunoglobulin G in women","volume":"89","author":"Baek","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2023.107850_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2016.02.006","article-title":"Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel","volume":"293","author":"Brill","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.clineuro.2023.107850_bib35","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/ene.14771","article-title":"Whole-exome sequencing reveals the major genetic factors contributing to neuromyelitis optica spectrum disorder in Chinese patients with aquaporin 4-IgG seropositivity","volume":"28","author":"Zhong","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1352458510382810","article-title":"Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population","volume":"17","author":"Deschamps","year":"2010","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2010.11.004","article-title":"HLA-DPB1*0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese","volume":"233","author":"Wang","year":"2011","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.clineuro.2023.107850_bib38","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/brain\/122.9.1689","article-title":"HLA-DPB1*0501-associated opticospinal multiple sclerosis: Clinical, neuroimaging and immunogenetic studies","volume":"122","author":"Yamasaki","year":"1999","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.neuroscience.2004.08.049","article-title":"Anchoring of aquaporin-4 in brain: molecular mechanisms and implications for the physiology and pathophysiology of water transport","volume":"129","author":"Amiry-Moghaddam","year":"2004","journal-title":"Neuroscience"},{"issue":"24","key":"10.1016\/j.clineuro.2023.107850_bib40","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1212\/01.wnl.0000286385.59836.e2","article-title":"Aquaporin-4, homeostasis, and neurologic disease","volume":"69","author":"Benarroch","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib41","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1007\/s12035-015-9171-9","article-title":"Association between the single nucleotide polymorphism and the level of aquaporin-4 protein expression in han and minority chinese with inflammatory demyelinating diseases of the central nervous system","volume":"53","author":"Chu","year":"2016","journal-title":"Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.clineuro.2023.107850_bib42","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14728222.2017.1398236","article-title":"The aquaporin-4 water channel as a potential drug target in neurological disorders","volume":"21","author":"Verkman","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10384-016-0441-5","article-title":"Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population","volume":"60","author":"Ogasawara","year":"2016","journal-title":"Jpn. J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.clineuro.2023.107850_bib44","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1212\/WNL.0b013e31822f045b","article-title":"Genetic analysis of aquaporin-4 in neuromyelitis optica","volume":"77","author":"Matiello","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.clineuro.2023.107850_bib45","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1007\/s12035-016-0070-5","article-title":"Association of CD40 gene polymorphisms with susceptibility to neuromyelitis optica spectrum disorders","volume":"54","author":"Shi","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"38","key":"10.1016\/j.clineuro.2023.107850_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001320","article-title":"The Fc receptor-like 3 polymorphisms (rs7528684, rs945635, rs3761959 and rs2282284) and the risk of neuromyelitis optica in A chinese population","volume":"94","author":"Lan","year":"2015","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib47","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1017\/S0317167100014001","article-title":"CD226 Gly307SeR Association with Neuromyelitis Optica in Southern Han Chinese","volume":"39","author":"Liu","year":"2012","journal-title":"Can. J. Neurol. Sci. J. Can. Des. Sci. Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib48","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1017\/S0317167100015973","article-title":"IL2RA allele increases risk of neuromyelitis optica in Southern Han Chinese","volume":"40","author":"Dai","year":"2013","journal-title":"Can. J. Neurol. Sci. J. Can. Des. Sci. Neurol."},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1352458508102085","article-title":"Is neuromyelitis optica associated with human leukocyte antigen?","volume":"15","author":"Z\u00e9phir","year":"2009","journal-title":"Mult. Scler. J."},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2990.2012.01304.x","article-title":"Associations of CD6, TNFRSF1A and IRF8 polymorphisms with risk of inflammatory demyelinating diseases","volume":"39","author":"Park","year":"2013","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.nbd.2009.10.013","article-title":"Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica","volume":"37","author":"Kim","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2013.08.031","article-title":"Putative association of GPC5 polymorphism with the risk of inflammatory demyelinating diseases","volume":"335","author":"Shin","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17469899.2020.1723416","article-title":"Environmental and genetic risk factors in the development of neuromyelitis optica","volume":"15","author":"Naser Moghadasi","year":"2020","journal-title":"Expert Rev. Ophthalmol."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13760-018-0900-5","article-title":"Environmental risk factors in neuromyelitis optica spectrum disorder: a case\u2013control study","volume":"118","author":"Eskandarieh","year":"2018","journal-title":"Acta Neurol. Belg."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12016-013-8361-3","article-title":"The implication of vitamin D and autoimmunity: a comprehensive review","volume":"45","author":"Yang","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.clineuro.2023.107850_bib56","doi-asserted-by":"crossref","unstructured":"S. Chen, G.P. Sims, X.X. Chen, Y.Y. Gu, S. Chen, P.E. Lipsky, Modulatory Effects of 1,25-Dihydroxyvitamin D<sub>3<\/sub> on Human B Cell Differentiation, The Journal of Immunology 179(3) (2007) 1634.","DOI":"10.4049\/jimmunol.179.3.1634"},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/cmi.2010.73","article-title":"Vitamin D and autoimmune thyroid diseases","volume":"8","author":"Kivity","year":"2011","journal-title":"Cell. Mol. Immunol."},{"issue":"9","key":"10.1016\/j.clineuro.2023.107850_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107274","article-title":"Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability","volume":"9","author":"Min","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clineuro.2023.107850_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2018.08.030","article-title":"Low vitamin D-25(OH) level in Indonesian multiple sclerosis and neuromyelitis optic patients","volume":"25","author":"Kusumadewi","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.clineuro.2023.107850_bib60","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s10072-015-2229-7","article-title":"Reduced serum vitamin D levels in neuromyelitis optica","volume":"36","author":"T\u00fcz\u00fcn","year":"2015","journal-title":"Neurol. Sci.: Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","article-title":"Vitamin D metabolism, mechanism of action, and clinical applications","volume":"21","author":"Bikle","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.clineuro.2023.107850_bib62","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2016.09.006","article-title":"Serum 25-hydroxyvitamin D3 is associated with disease status in patients with neuromyelitis optica spectrum disorders in south China","volume":"299","author":"Shan","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.clineuro.2023.107850_bib63","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1212\/WNL.0b013e3181b59c40","article-title":"Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis","volume":"73","author":"Hedstr\u00f6m","year":"2009","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.clineuro.2023.107850_bib64","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archneurol.2009.122","article-title":"Smoking and disease progression in multiple sclerosis","volume":"66","author":"Healy","year":"2009","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib65","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrneurol.2010.1","article-title":"Environmental factors and their timing in adult-onset multiple sclerosis","volume":"6","author":"Handel","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib66","first-page":"93","article-title":"Association of cigarette smoking with neuromyelitis optica-immunoglobulin G sero-positivity in neuromyelitis optica spectrum disorder","volume":"18","author":"Eskandarieh","year":"2019","journal-title":"Iran. J. Neurol."},{"key":"10.1016\/j.clineuro.2023.107850_bib67","first-page":"246","article-title":"Neuromyelitis Optica spectrum disorder and its environmental risk factors for Nmo-IgG Sero-positivity","volume":"26","author":"Eskandarieh","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2023.107850_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102773","article-title":"The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis","volume":"49","author":"Messina","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"37","key":"10.1016\/j.clineuro.2023.107850_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027234","article-title":"A preliminary study of association of cigarette smoking with risk of neuromyelitis optica spectrum disorder","volume":"100","author":"Yang","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.clineuro.2023.107850_bib70","series-title":"ACTRIMS Forum 2018","article-title":"Diet and Neuromyelitis Optica Spectrum Disorder; Association between Food Group Intakes and Disability in Patients with Nmosd","author":"Maljaei","year":"2018"},{"key":"10.1016\/j.clineuro.2023.107850_bib71","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.msard.2019.03.028","article-title":"The association between dietary sugar intake and neuromyelitis optica spectrum disorder: A case\u2013control study","volume":"31","author":"Rezaeimanesh","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2023.107850_bib72","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.msard.2018.10.049","article-title":"Various types of dietary sugar and neuromyelitis optica spectrum disorder","volume":"26","author":"Rezaeimanesh","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2023.107850_bib73","first-page":"1","article-title":"Low carbohydrate diet score and odds of neuromyelitis optica spectrum disorder: A case-control study","author":"Rezaeimanesh","year":"2020","journal-title":"Int. J. Vitam. Nutr. Res. Int. Z. Vitam. Ernahr. J. Int. De. Vitaminol. Et. De. Nutr."},{"key":"10.1016\/j.clineuro.2023.107850_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106903","article-title":"The association between dietary total antioxidant capacity and NMO-IgG seropositivity in patients with neuromyelitis optica spectrum disorder","volume":"209","author":"Rezaeimanesh","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib75","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-010-0704-z","article-title":"Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination","volume":"120","author":"Sharma","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"11","key":"10.1016\/j.clineuro.2023.107850_bib76","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00415-009-5171-x","article-title":"Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution","volume":"256","author":"Bizzoco","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2023.107850_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102544","article-title":"Stressful life events, socioeconomic status, and the risk of neuromyelitis optica spectrum disorder: A population-based case-control study","volume":"46","author":"Rafiee","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib78","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/1471-2334-14-470","article-title":"Fatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosis","volume":"14","author":"Sridhar","year":"2014","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/brain\/100.2.223","article-title":"Acute necrotic myelopathy with pulmonary tuberculosis","volume":"100","author":"Hughes","year":"1977","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib80","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/jnnp.73.4.429","article-title":"Optic neuromyelitis syndrome in Brazilian patients","volume":"73","author":"Papais-Alvarenga","year":"2002","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib81","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1212\/WNL.40.6.934","article-title":"Neuromyelitis optica (Devic's syndrome) and pulmonary tuberculosis","volume":"40","author":"Silber","year":"1990","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.clineuro.2023.107850_bib82","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.5588\/ijtld.10.0780","article-title":"Neuromyelitis optica and pulmonary tuberculosis: a case-control study","volume":"15","author":"Zatjirua","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib83","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5588\/ijtld.13.0911","article-title":"Relapsing neuromyelitis optica temporally related to recurrent pulmonary tuberculosis","volume":"18","author":"Brey","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib84","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s13256-021-03002-1","article-title":"Neuromyelitis optica and concomitant pulmonary tuberculosis: a case report","volume":"15","author":"Saied","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.clineuro.2023.107850_bib85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jneuroim.2018.07.007","article-title":"High levels of antibodies against PtpA and PknG secreted by <em>Mycobacterium avium<\/em> ssp. <em>paratuberculosis<\/em> are present in neuromyelitis optica spectrum disorder and multiple sclerosis patients","volume":"323","author":"Slavin","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"15","key":"10.1016\/j.clineuro.2023.107850_bib86","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1056\/NEJMra020542","article-title":"Helicobacter pylori Infection","volume":"347","author":"Suerbaum","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"8390","key":"10.1016\/j.clineuro.2023.107850_bib87","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(84)91816-6","article-title":"Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration","volume":"323","author":"Marshall","year":"1984","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib88","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/gut.35.6.742","article-title":"Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection","volume":"35","author":"Malaty","year":"1994","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.clineuro.2023.107850_bib89","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/1352458509348961","article-title":"Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica","volume":"15","author":"Wei","year":"2009","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib90","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000345838","article-title":"Helicobacter pylori Infection in Neuromyelitis Optica and Multiple Sclerosis","volume":"20","author":"Long","year":"2013","journal-title":"Neuroimmunomodulation"},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jnnp-2012-302925","article-title":"Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status","volume":"84","author":"Yoshimura","year":"2013","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"issue":"38","key":"10.1016\/j.clineuro.2023.107850_bib92","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1523\/JNEUROSCI.2674-08.2008","article-title":"Systemic Inflammation Alters the Kinetics of Cerebrovascular Tight Junction Disruption after Experimental Stroke in Mice","volume":"28","author":"McColl","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clineuro.2023.107850_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577126","article-title":"Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study","volume":"339","author":"Shi","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"11","key":"10.1016\/j.clineuro.2023.107850_bib94","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/ene.12072","article-title":"Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system","volume":"20","author":"Banati","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clineuro.2023.107850_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102217","article-title":"Characteristic of gut microbiota in southeastern Chinese patients with neuromyelitis optica spectrum disorders","volume":"44","author":"Zhang","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib96","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00005072-198205000-00002","article-title":"Spinal Cord and Optic Nerve Demyelination in Experimental Herpes Simplex Virus Type 2 Infection","volume":"41","author":"Martin","year":"1982","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib97","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the Epstein-Barr virus and risk of multiple sclerosis","volume":"67","author":"Levin","year":"2010","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.clineuro.2023.107850_bib98","first-page":"881","article-title":"Association between Multiple Sclerosis or Neuromyelitis Optica and Epstein-Barr Virus","volume":"67","author":"Mori","year":"2015","journal-title":"Brain Nerve"},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib99","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.clineuro.2023.107850_bib100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.clineuro.2023.107850_bib101","article-title":"Natural killer cells in innate immunity and cancer","volume":"31","author":"Becknell","year":"2008","journal-title":"J. Immunother. (Hagerstown, Md.: 1997)"},{"issue":"12","key":"10.1016\/j.clineuro.2023.107850_bib102","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.tins.2019.09.006","article-title":"Astroglia-derived ATP modulates CNS neuronal circuits","volume":"42","author":"Illes","year":"2019","journal-title":"Trends Neurosci."},{"issue":"7","key":"10.1016\/j.clineuro.2023.107850_bib103","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/intimm\/dxx037","article-title":"Efficiency of antibody therapy in demyelinating diseases","volume":"29","author":"Akaishi","year":"2017","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib104","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/ajts.AJTS_111_16","article-title":"Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica","volume":"11","author":"Batra","year":"2017","journal-title":"Asian J. Transfus. Sci."},{"key":"10.1016\/j.clineuro.2023.107850_bib105","unstructured":"(!!! INVALID CITATION !!! 107)."},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib106","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib107","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib108","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clineuro.2023.107850_bib109","doi-asserted-by":"crossref","first-page":"7180632","DOI":"10.1155\/2017\/7180632","article-title":"Mitochondrial uncoupler prodrug of 2,4-dinitrophenol, MP201, prevents neuronal damage and preserves vision in experimental optic neuritis","volume":"2017","author":"Khan","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib110","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib111","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","article-title":"Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker","volume":"80","author":"Misu","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2023.107850_bib112","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","article-title":"Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks","volume":"421","author":"Uzawa","year":"2013","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib113","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"issue":"7555","key":"10.1016\/j.clineuro.2023.107850_bib114","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature14335","article-title":"Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo","volume":"522","author":"Najm","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2023.107850_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.clineuro.2023.107850_bib117","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"14","key":"10.1016\/j.clineuro.2023.107850_bib118","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","volume":"26","author":"Salama","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib119","first-page":"82","article-title":"Association of optic neuritis with neuromyelitis optica spectrum disorder and multiple sclerosis in korea","volume":"33","author":"Kim","year":"2019","journal-title":"kjo"},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib120","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/1352458520933884","article-title":"Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD","volume":"27","author":"Kunchok","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib121","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib122","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clineuro.2023.107850_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00201","article-title":"The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders","volume":"10","author":"H\u00e4usser-Kinzel","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.clineuro.2023.107850_bib124","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","article-title":"B cells in autoimmune and neurodegenerative central nervous system diseases","volume":"20","author":"Sabatino","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib125","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.clineuro.2023.107850_bib126","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41582-020-0381-z","article-title":"The B cell immunobiology that underlies CNS autoantibody-mediated diseases","volume":"16","author":"Sun","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.clineuro.2023.107850_bib127","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/eji.202048643","article-title":"Transcriptomic profiling of bovine blood dendritic cells and monocytes following TLR stimulation","volume":"50","author":"Barut","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clineuro.2023.107850_bib128","unstructured":"(!!! INVALID CITATION !!! 46)."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2377-10-113","article-title":"Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"10","author":"Uzawa","year":"2010","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000329576","article-title":"Association of Th1\/Th2-Related Chemokine Receptors in Peripheral T Cells with Disease Activity in Patients with Multiple Sclerosis and Neuromyelitis Optica","volume":"66","author":"Shimizu","year":"2011","journal-title":"Eur. Neurol."},{"issue":"9451","key":"10.1016\/j.clineuro.2023.107850_bib131","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib132","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/rheumatology\/kes425","article-title":"Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine","volume":"52","author":"Fischer-Betz","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.clineuro.2023.107850_bib133","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.12118","article-title":"Immunology of neuromyelitis optica: a T cell-B cell collaboration","volume":"1283","author":"Mitsdoerffer","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib134","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2023.107850_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2016.09.011","article-title":"CD14+CD16++ monocytes are increased in patients with NMO and are selectively suppressed by glucocorticoids therapy","volume":"300","author":"Zeng","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2023.107850_bib137","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib138","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib139","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1941874412466873","article-title":"Fulminant Demyelinating Diseases","volume":"3","author":"Rahmlow","year":"2013","journal-title":"Neurohospitalist"},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice \u2013 Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib141","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib142","first-page":"36","article-title":"Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels","volume":"9","author":"Kim","year":"2013","journal-title":"jcn"},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib143","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/practneurol-2017-001787","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations","volume":"19","author":"Jury\u0144czyk","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.clineuro.2023.107850_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101506","article-title":"A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX","volume":"38","author":"Songthammawat","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib145","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00415-012-6692-2","article-title":"Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica","volume":"260","author":"Kageyama","year":"2013","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib146","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10384-016-0454-0","article-title":"Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica","volume":"60","author":"Nobuyoshi","year":"2016","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.clineuro.2023.107850_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102325","article-title":"Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD)","volume":"44","author":"Li","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.clineuro.2023.107850_bib148","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cyto.2013.07.019","article-title":"Post-acute serum eosinophil and neutrophil-associated cytokine\/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms \u2013 A pilot study","volume":"64","author":"Michael","year":"2013","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.clineuro.2023.107850_bib149","first-page":"65","article-title":"The effect of intravenous immunoglobulin on neuromyelitis optica","volume":"28","author":"Magraner","year":"2013","journal-title":"Neurol. (Engl. Ed. )"},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib150","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: The past, the present, and the future","volume":"55","author":"Patel","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib151","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","article-title":"Mechanism of action of mycophenolate mofetil","volume":"17","author":"Ransom","year":"1995","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib152","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107850_bib153","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar1957","article-title":"Anti-inflammatory and immunosuppressive drugs and reproduction","volume":"8","author":"\u00d8stensen","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib154","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jca.21686","article-title":"Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica","volume":"34","author":"Lipphardt","year":"2019","journal-title":"J. Clin. Apher."},{"issue":"11","key":"10.1016\/j.clineuro.2023.107850_bib155","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.clineuro.2023.107850_bib156","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: First Approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib157","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/14737175.2020.1757434","article-title":"Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options","volume":"20","author":"Rosso","year":"2020","journal-title":"Expert Rev. Neurother."},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib158","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tmrv.2019.09.004","article-title":"Eculizumab and beyond: the past, present, and future of complement therapeutics","volume":"33","author":"Patriquin","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.clineuro.2023.107850_bib159","first-page":"75","article-title":"Anti-aquaporin-4 antibodies in neuromyelitis optica: how to prove their pathogenetic relevance?","volume":"15","author":"Bradl","year":"2008","journal-title":"Int. MS J."},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib160","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1046\/j.1365-2141.2002.03935.x","article-title":"Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab","volume":"119","author":"Golay","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.clineuro.2023.107850_bib161","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib162","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.clineuro.2023.107850_bib163","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib164","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Anti\u2013interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.clineuro.2023.107850_bib165","article-title":"Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol. R. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2023.107850_bib166","doi-asserted-by":"crossref","unstructured":"D.M. Wingerchuk, K. Fujihara, J. Palace, A. Berthele, M. Levy, H.J. Kim, I. Nakashima, C. Oreja-Guevara, K.-C. Wang, L. Miller, S. Shang, G. Sabatella, M. Yountz, S.J. Pittock, P.S. Group, Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD, 89(6) (2021) 1088\u20131098.","DOI":"10.1002\/ana.26049"},{"key":"10.1016\/j.clineuro.2023.107850_bib167","doi-asserted-by":"crossref","unstructured":"S.J. Pittock, K. Fujihara, J. Palace, A. Berthele, H.J. Kim, C. Oreja-Guevara, I. Nakashima, M. Levy, S. Shang, M. Yountz, L. Miller, R. Armstrong, D.M. Wingerchuk, Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension, 28(3) (2022) 480\u2013486.","DOI":"10.1177\/13524585211038291"},{"issue":"8","key":"10.1016\/j.clineuro.2023.107850_bib168","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/00207454.2016.1242587","article-title":"Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future","volume":"127","author":"Lin","year":"2017","journal-title":"Int. J. Neurosci."},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib169","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.clineuro.2023.107850_bib170","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/brb3.75","article-title":"Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1 G93A mouse model of amyotrophic lateral sclerosis","volume":"2","author":"Lerman","year":"2012","journal-title":"Brain Behav."},{"issue":"4","key":"10.1016\/j.clineuro.2023.107850_bib171","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ajpath.2013.06.017","article-title":"Galectin-3 Modulates Th17 Responses by Regulating Dendritic Cell Cytokines","volume":"183","author":"Fermin Lee","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.clineuro.2023.107850_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110450","article-title":"Could Galectin-3 be a key player in the etiology of neuromyelitis optica spectrum disorder?","volume":"146","author":"Ramakrishnan","year":"2021","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.clineuro.2023.107850_bib173","doi-asserted-by":"crossref","first-page":"2817252","DOI":"10.1155\/2017\/2817252","article-title":"Targeting Oxidative Stress for Treatment of Glaucoma and Optic Neuritis","volume":"2017","author":"Kimura","year":"2017","journal-title":"Oxid. Med. Cell. Longev."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846723002664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846723002664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:45:22Z","timestamp":1759589122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846723002664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":173,"alternative-id":["S0303846723002664"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2023.107850","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs)","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2023.107850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107850"}}